deltatrials
Completed PHASE1 NCT00199212

PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2

A Phase I, Open Label, Dose-escalating Study of the Proteasome Inhibitor PS-341 in Combination With Two Schedules of Herceptin, in Patients With Advanced Breast Cancer That Overexpresses HER-2

Sponsor: Jules Bordet Institute

Conditions Carcinoma Breast Stage IV
Interventions Combination of trastuzumab and PS-341
Updated 5 times since 2017 Last updated: Feb 23, 2011 Started: Oct 31, 2003 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This PHASE1 trial investigates Carcinoma Breast Stage IV and is currently completed. Jules Bordet Institute leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jules Bordet Institute
Data source: Jules Bordet Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Brussels, Belgium